Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Published

Journal Article

BACKGROUND: To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). METHODS: A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed. RESULTS: Of 277 patients (median age: 58years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C+Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7months, and median overall survival (OS) was 14.3 and 10.5months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n=19, OS of 20.4months), taxanes (n=55, OS of 20.2months), gemcitabine (n=106, OS of 14.1months), topotecan (n=43, OS of 13months), and cyclophosphamide (n=21, OS of 13months). There was no significant difference in toxicities between the C+Bev vs. Bev alone group. CONCLUSION: This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.

Full Text

Duke Authors

Cited Authors

  • Fuh, KC; Secord, AA; Bevis, KS; Huh, W; ElNaggar, A; Blansit, K; Previs, R; Tillmanns, T; Kapp, DS; Chan, JK

Published Date

  • December 2015

Published In

Volume / Issue

  • 139 / 3

Start / End Page

  • 413 - 418

PubMed ID

  • 26144600

Pubmed Central ID

  • 26144600

Electronic International Standard Serial Number (EISSN)

  • 1095-6859

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2015.06.041

Language

  • eng

Conference Location

  • United States